{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:22:06Z","timestamp":1794266526957,"version":"4.9.0"},"reference-count":92,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.2967\/jnumed.121.262687","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T13:54:10Z","timestamp":1631195650000},"page":"5-13","source":"Crossref","is-referenced-by-count":89,"title":["Harnessing\n                    <b>\u03b1<\/b>\n                    -Emitting Radionuclides for Therapy: Radiolabeling Method Review"],"prefix":"10.2967","volume":"63","author":[{"given":"Hua","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin J.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Orvig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Scott","family":"Wilbur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina F.","family":"Ramogida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery","family":"Radchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Schaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"2022032309401360000_63.1.5.1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/ijms17010033","article-title":"Targeted radionuclide therapy of human tumors","volume":"17","author":"Gudkov","year":"2015","journal-title":"Int J Mol Sci."},{"key":"2022032309401360000_63.1.5.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.160"},{"key":"2022032309401360000_63.1.5.3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1874471011666180502104524","article-title":"An overview of targeted alpha therapy with 225actinium and 213bismuth","volume":"11","author":"Morgenstern","year":"2018","journal-title":"Curr Radiopharm."},{"key":"2022032309401360000_63.1.5.4","doi-asserted-by":"publisher","DOI":"10.2174\/1874471011104040306"},{"key":"2022032309401360000_63.1.5.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058651"},{"key":"2022032309401360000_63.1.5.6","doi-asserted-by":"crossref","first-page":"e64730","DOI":"10.1371\/journal.pone.0064730","article-title":"Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation","volume":"8","author":"Wulbrand","year":"2013","journal-title":"PLoS One."},{"key":"2022032309401360000_63.1.5.7","first-page":"55","article-title":"Therapeutic targeting of tumor hypoxia and necrosis with antibody \u03b1-radioconjugates","volume":"1","author":"Staudacher","year":"2018","journal-title":"Antib Ther."},{"key":"2022032309401360000_63.1.5.8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.semnuclmed.2020.02.003","article-title":"Supply and clinical application of actinium-225 and bismuth-213","volume":"50","author":"Morgenstern","year":"2020","journal-title":"Semin Nucl Med."},{"key":"2022032309401360000_63.1.5.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673"},{"key":"2022032309401360000_63.1.5.10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/ph8020321","article-title":"A critical review of alpha radionuclide therapy: how to deal with recoiling daughters?","volume":"8","author":"de Kruijff","year":"2015","journal-title":"Pharmaceuticals (Basel)."},{"key":"2022032309401360000_63.1.5.11","doi-asserted-by":"crossref","first-page":"20665","DOI":"10.1021\/acsomega.9b02851","article-title":"Predicting stability constants for terbium(III) complexes with dipicolinic acid and 4-substituted dipicolinic acid analogues using density functional theory","volume":"4","author":"Chen","year":"2019","journal-title":"ACS Omega."},{"key":"2022032309401360000_63.1.5.12","doi-asserted-by":"crossref","first-page":"7700","DOI":"10.1021\/ic100447m","article-title":"Probing the structure, conformation, and stereochemical exchange in a family of lanthanide complexes derived from tetrapyridyl-appended cyclen","volume":"49","author":"Natrajan","year":"2010","journal-title":"Inorg Chem."},{"key":"2022032309401360000_63.1.5.13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41181-016-0008-2","article-title":"Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics","volume":"1","author":"M\u00fcller","year":"2017","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2022032309401360000_63.1.5.14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3390\/ph7030353","article-title":"Folate receptor targeted alpha-therapy using terbium-149","volume":"7","author":"M\u00fcller","year":"2014","journal-title":"Pharmaceuticals (Basel)."},{"key":"2022032309401360000_63.1.5.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-003-1413-9"},{"key":"2022032309401360000_63.1.5.16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/1874471011104030214","article-title":"Chemical and radiochemical considerations in radiolabeling with \u03b1-emitting radionuclides","volume":"4","author":"Wilbur","year":"2012","journal-title":"Curr Radiopharm."},{"key":"2022032309401360000_63.1.5.17","doi-asserted-by":"publisher","DOI":"10.2174\/1874471010801030144"},{"key":"2022032309401360000_63.1.5.18","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2012.1292"},{"key":"2022032309401360000_63.1.5.19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.nucmedbio.2014.12.011","article-title":"Stability and in\u00a0vivo behavior of Rh[16aneS4-diol]211At complex: a potential precursor for astatine radiopharmaceuticals","volume":"42","author":"Pruszy\u0144ski","year":"2015","journal-title":"Nucl Med Biol."},{"key":"2022032309401360000_63.1.5.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.062604"},{"key":"2022032309401360000_63.1.5.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.046938"},{"key":"2022032309401360000_63.1.5.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.049833"},{"key":"2022032309401360000_63.1.5.23","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.jmir.2019.03.090","article-title":"PARP-1 targeted alpha-emitting radiotherapeutics: an examination of potential toxicity [abstract]","volume":"50(suppl 1)","author":"Mansfield","year":"2019","journal-title":"J Med Imaging Radiat Sci."},{"key":"2022032309401360000_63.1.5.24","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0837"},{"key":"2022032309401360000_63.1.5.25","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1039\/D0SC05191H","article-title":"Investigation on the reactivity of nucleophilic radiohalogens with arylboronic acids in water: access to an efficient single-step method for the radioiodination and astatination of antibodies","volume":"12","author":"Berdal","year":"2020","journal-title":"Chem Sci."},{"key":"2022032309401360000_63.1.5.26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nano10071366","article-title":"Nanoparticles in targeted alpha therapy","volume":"10","author":"Majkowska-Pilip","year":"2020","journal-title":"Nanomaterials (Basel)."},{"key":"2022032309401360000_63.1.5.27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13550-018-0431-3","article-title":"Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics","volume":"8","author":"\u0160ime\u010dek","year":"2018","journal-title":"EJNMMI Res."},{"key":"2022032309401360000_63.1.5.28","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.nucmedbio.2014.12.007","article-title":"Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes","volume":"42","author":"Wilson","year":"2015","journal-title":"Nucl Med Biol."},{"key":"2022032309401360000_63.1.5.29","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.nucmedbio.2013.01.012","article-title":"Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies","volume":"40","author":"Kang","year":"2013","journal-title":"Nucl Med Biol."},{"key":"2022032309401360000_63.1.5.30","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1021\/bc100586y","article-title":"Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted \u03b1-radioimmunotherapy applications","volume":"22","author":"Song","year":"2011","journal-title":"Bioconjug Chem."},{"key":"2022032309401360000_63.1.5.31","doi-asserted-by":"crossref","unstructured":"Slikkerveer A Noach LA Tytgat GNJ Van Der Voet GB De Wolff FA . Comparison of enhanced elimination of bismuth in humans after treatment with meso-2,3-dimercaptosuccinic acid and D,L-2,3-dimercaptopropane-1-sulfonic acid. In: Analyst. Vol 123. The Royal Society of Chemistry; 1998:91\u201392.","DOI":"10.1039\/a704945e"},{"key":"2022032309401360000_63.1.5.32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0020-1693(95)04708-5","article-title":"Lead(II) complexes of 1,4,7,10-tetraazacyclododecane-N,N\u2032,N\u2033,N\u2034-tetraacetate: solution chemistry and application to tumor localization with 203Pb labeled monoclonal antibodies","volume":"239","author":"Pippin","year":"1995","journal-title":"Inorg Chim Acta."},{"key":"2022032309401360000_63.1.5.33","doi-asserted-by":"publisher","DOI":"10.1039\/c0dt01387k"},{"key":"2022032309401360000_63.1.5.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2005.06.009"},{"key":"2022032309401360000_63.1.5.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0619"},{"key":"2022032309401360000_63.1.5.36","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)02119-1"},{"key":"2022032309401360000_63.1.5.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8051(99)00086-4"},{"key":"2022032309401360000_63.1.5.38","first-page":"1881","article-title":"Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice","volume":"40","author":"Tan","year":"2012","journal-title":"Int J Oncol."},{"key":"2022032309401360000_63.1.5.39","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/COC.0000000000000353","article-title":"Safety and outcome measures of first-in-human intraperitoneal \u03b1 radioimmunotherapy with 212Pb-TCMC-trastuzumab","volume":"41","author":"Meredith","year":"2018","journal-title":"Am J Clin Oncol."},{"key":"2022032309401360000_63.1.5.40","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.229393"},{"key":"2022032309401360000_63.1.5.41","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.3390\/ijms22094815","article-title":"Evaluation of the PSMA-binding ligand 212Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer","volume":"22","author":"Stenberg","year":"2021","journal-title":"Int J Mol Sci."},{"key":"2022032309401360000_63.1.5.42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.nucmedbio.2017.01.003","article-title":"B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models","volume":"47","author":"Kasten","year":"2017","journal-title":"Nucl Med Biol."},{"key":"2022032309401360000_63.1.5.43","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41181-021-00121-4","article-title":"Production, purification, and radiolabeling of the 203Pb\/212Pb theranostic pair","volume":"6","author":"McNeil","year":"2021","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2022032309401360000_63.1.5.44","doi-asserted-by":"crossref","first-page":"32357","DOI":"10.1039\/C9RA07293D","article-title":"A comparative evaluation of calix[4]arene-1,3-crown-6 as a ligand for selected divalent cations of radiopharmaceutical interest","volume":"9","author":"Bauer","year":"2019","journal-title":"RSC Advances."},{"key":"2022032309401360000_63.1.5.45","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1039\/D0SC06867E","article-title":"Towards the stable chelation of radium for biomedical applications with an 18-membered macrocyclic ligand","volume":"12","author":"Abou","year":"2021","journal-title":"Chem Sci."},{"key":"2022032309401360000_63.1.5.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8043(01)00282-2"},{"key":"2022032309401360000_63.1.5.47","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.138347"},{"key":"2022032309401360000_63.1.5.48","doi-asserted-by":"publisher","DOI":"10.1126\/science.1064126"},{"key":"2022032309401360000_63.1.5.49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4647"},{"key":"2022032309401360000_63.1.5.50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088239"},{"key":"2022032309401360000_63.1.5.51","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-2023-6"},{"key":"2022032309401360000_63.1.5.52","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7150\/thno.17117","article-title":"Preclinical melanoma imaging with 68Ga-labeled \u03b1-melanocyte-stimulating hormone derivatives using PET","volume":"7","author":"Zhang","year":"2017","journal-title":"Theranostics."},{"key":"2022032309401360000_63.1.5.53","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.2967\/jnumed.118.217240","article-title":"Melanocortin 1 receptor\u2013targeted \u03b1-particle therapy for metastatic uveal melanoma","volume":"60","author":"Tafreshi","year":"2019","journal-title":"J Nucl Med."},{"key":"2022032309401360000_63.1.5.54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0800"},{"key":"2022032309401360000_63.1.5.55","doi-asserted-by":"crossref","first-page":"11435","DOI":"10.1002\/chem.202002999","article-title":"Synthesis and evaluation of a new macrocyclic actinium\u2010225 chelator, quality control and in\u00a0vivo evaluation of 225Ac\u2010crown\u2010\u03b1MSH peptide","volume":"26","author":"Yang","year":"2020","journal-title":"Chemistry."},{"key":"2022032309401360000_63.1.5.56","doi-asserted-by":"crossref","first-page":"14712","DOI":"10.1002\/anie.201709532","article-title":"An eighteen-membered macrocyclic ligand for actinium-225 targeted alpha therapy","volume":"56","author":"Thiele","year":"2017","journal-title":"Angew Chem Int Ed Engl."},{"key":"2022032309401360000_63.1.5.57","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219592"},{"issue":"suppl 1","key":"2022032309401360000_63.1.5.58","first-page":"1235","article-title":"A novel actinium bifunctional chelator Crown and biodistribution of Ac-225-Crown-TATE [abstract]","volume":"61","author":"Yang","year":"2020","journal-title":"J Nucl Med."},{"key":"2022032309401360000_63.1.5.59","doi-asserted-by":"publisher","DOI":"10.1021\/jm990141f"},{"key":"2022032309401360000_63.1.5.60","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/108497802753773847","article-title":"Actinium-225 conjugates of MAb CC49 and humanized \u0394CH2CC49","volume":"17","author":"Kennel","year":"2002","journal-title":"Cancer Biother Radiopharm."},{"key":"2022032309401360000_63.1.5.61","doi-asserted-by":"publisher","DOI":"10.1089\/108497800414329"},{"key":"2022032309401360000_63.1.5.62","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8043(02)00167-7"},{"key":"2022032309401360000_63.1.5.63","doi-asserted-by":"crossref","first-page":"19404","DOI":"10.1021\/jacs.9b10354","article-title":"Advancing chelation chemistry for actinium and other +3 f-elements, Am, Cm, and La","volume":"141","author":"Stein","year":"2019","journal-title":"J Am Chem Soc."},{"key":"2022032309401360000_63.1.5.64","doi-asserted-by":"crossref","unstructured":"Thiele NA Wilson JJ . Actinium-225 for targeted \u03b1 therapy: coordination chemistry and current chelation approaches. In: Cancer Biotherapy and Radiopharmaceuticals. Vol 33. Mary Ann Liebert Inc.; 2018:336\u2013348.","DOI":"10.1089\/cbr.2018.2494"},{"key":"2022032309401360000_63.1.5.65","doi-asserted-by":"crossref","unstructured":"Li L Rousseau J Jaraquemada-Pel\u00e1ez M de G . 225Ac-H 4 py4pa for targeted alpha therapy. Bioconjug Chem. 2021;32:1348\u20131363.","DOI":"10.1021\/acs.bioconjchem.0c00171"},{"key":"2022032309401360000_63.1.5.66","doi-asserted-by":"crossref","first-page":"15945","DOI":"10.1002\/chem.201702284","article-title":"Octadentate picolinic acid-based bispidine ligand for radiometal ions","volume":"23","author":"Comba","year":"2017","journal-title":"Chemistry."},{"key":"2022032309401360000_63.1.5.67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s41181-019-0072-5","article-title":"Evaluation of polydentate picolinic acid chelating ligands and an \u03b1-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced 225Ac","volume":"4","author":"Ramogida","year":"2019","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2022032309401360000_63.1.5.68","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1021\/acs.inorgchem.1c00152","article-title":"Chemical promiscuity of non-macrocyclic multidentate chelating ligands for radiometal ions: H4neunpa-NH2 vs H4noneunpa","volume":"60","author":"Wharton","year":"2021","journal-title":"Inorg Chem."},{"key":"2022032309401360000_63.1.5.69","first-page":"101","article-title":"Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents","volume":"24","author":"Henriksen","year":"2004","journal-title":"Anticancer Res."},{"key":"2022032309401360000_63.1.5.70","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.nucmedbio.2004.05.001","article-title":"227Th-EDTMP: a potential therapeutic agent for bone metastasis","volume":"31","author":"Washiyama","year":"2004","journal-title":"Nucl Med Biol."},{"key":"2022032309401360000_63.1.5.71","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/0925-8388(94)90917-2","article-title":"Kinetically and thermodynamically stable isomers of thorium chelates of polyaza polycarboxylic macrocycles","volume":"213","author":"Jacques","year":"1994","journal-title":"J Alloys Compd."},{"key":"2022032309401360000_63.1.5.72","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.1002\/chem.201700493","article-title":"Coordination of tetravalent actinides (An=ThIV, UIV, NpIV, PuIV) with DOTA: from dimers to hexamers","volume":"23","author":"Tamain","year":"2017","journal-title":"Chemistry."},{"key":"2022032309401360000_63.1.5.73","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1021\/acs.inorgchem.9b00736","article-title":"Synthesis and crystallographic characterization of the tetravalent actinide-DOTA complexes [AnIV(\u03ba8-DOTA)(DMSO)] (An = Th, U)","volume":"58","author":"Kent","year":"2019","journal-title":"Inorg Chem."},{"key":"2022032309401360000_63.1.5.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2005.12.004"},{"key":"2022032309401360000_63.1.5.75","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1089\/cbr.2006.321","article-title":"Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability","volume":"22","author":"Larsen","year":"2007","journal-title":"Cancer Biother Radiopharm."},{"key":"2022032309401360000_63.1.5.76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042345"},{"key":"2022032309401360000_63.1.5.77","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/jlcr.3875","article-title":"Thorium chelators for targeted alpha therapy: rapid chelation of thorium-226","volume":"63","author":"Ferrier","year":"2020","journal-title":"J Labelled Compd Radiopharm."},{"key":"2022032309401360000_63.1.5.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.07.034"},{"key":"2022032309401360000_63.1.5.79","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0251"},{"key":"2022032309401360000_63.1.5.80","doi-asserted-by":"crossref","first-page":"56311","DOI":"10.18632\/oncotarget.16910","article-title":"Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in\u00a0vitro and in\u00a0vivo models of renal cell carcinoma","volume":"8","author":"Hagemann","year":"2017","journal-title":"Oncotarget."},{"key":"2022032309401360000_63.1.5.81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3476"},{"key":"2022032309401360000_63.1.5.82","doi-asserted-by":"crossref","first-page":"14337","DOI":"10.1021\/acs.inorgchem.8b02430","article-title":"Solution thermodynamics and kinetics of metal complexation with a hydroxypyridinone chelator designed for thorium-227 targeted alpha therapy","volume":"57","author":"Deblonde","year":"2018","journal-title":"Inorg Chem."},{"key":"2022032309401360000_63.1.5.83","doi-asserted-by":"crossref","first-page":"9106","DOI":"10.1021\/ja503456r","article-title":"A macrocyclic chelator with unprecedented Th4+ affinity","volume":"136","author":"Pham","year":"2014","journal-title":"J Am Chem Soc."},{"key":"2022032309401360000_63.1.5.84","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1021\/cr990114x","article-title":"Rational design of sequestering agents for plutonium and other actinides","volume":"103","author":"Gorden","year":"2003","journal-title":"Chem Rev."},{"key":"2022032309401360000_63.1.5.85","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jinorgbio.2009.08.010","article-title":"Spectroscopic study of the interaction of U(VI) with transferrin and albumin for speciation of U(VI) under blood serum conditions","volume":"103","author":"Montavon","year":"2009","journal-title":"J Inorg Biochem."},{"key":"2022032309401360000_63.1.5.86","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1039\/B918426K","article-title":"Investigation of para-sulfonatocalix[n]arenes [n = 6, 8] as potential chelates for 230U","volume":"39","author":"Montavon","year":"2010","journal-title":"Dalton Trans."},{"key":"2022032309401360000_63.1.5.87","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10967-007-0931-5","article-title":"Complexation of uranium (VI) with the siderophore desferrioxamine B","volume":"273","author":"Mullen","year":"2007","journal-title":"J Radioanal Nucl Chem."},{"key":"2022032309401360000_63.1.5.88","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1021\/ja201511u","article-title":"Hexadentate terephthalamide(bis-hydroxypyridinone) ligands for uranyl chelation: structural and thermodynamic consequences of ligand variation 1","volume":"133","author":"Szigethy","year":"2011","journal-title":"J Am Chem Soc."},{"key":"2022032309401360000_63.1.5.89","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1002\/chem.201905357","article-title":"On the aqueous chemistry of the UIV\u2013DOTA complex","volume":"26","author":"Dovrat","year":"2020","journal-title":"Chemistry."},{"key":"2022032309401360000_63.1.5.90","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/acs.inorgchem.0c03088","article-title":"Controlling the reduction of chelated uranyl to stable tetravalent uranium coordination complexes in aqueous solution","volume":"60","author":"Carter","year":"2021","journal-title":"Inorg Chem."},{"key":"2022032309401360000_63.1.5.91","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1021\/ic9606439","article-title":"Complexation of thorium(IV) and uranium(IV) by a hexaacetic hexaaza macrocycle: kinetic and thermodynamic topomers of actinide chelates with a large cavity ligand","volume":"35","author":"Jacques","year":"1996","journal-title":"Inorg Chem."},{"key":"2022032309401360000_63.1.5.92","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41557-020-00598-7","article-title":"Developing the 134Ce and 134La pair as companion positron emission tomography diagnostic isotopes for 225Ac and 227Th radiotherapeutics","volume":"13","author":"Bailey","year":"2021","journal-title":"Nat Chem."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.262687","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T12:43:31Z","timestamp":1648039411000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.262687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,3]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.2967\/jnumed.121.262687"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.262687","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]}}}